Harrow Eye Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HARROW EYE, and what generic alternatives to HARROW EYE drugs are available?
HARROW EYE has nineteen approved drugs.
There are twenty-nine US patents protecting HARROW EYE drugs.
There are three hundred and fifty-four patent family members on HARROW EYE drugs in forty-two countries and twenty-five supplementary protection certificates in ten countries.
Drugs and US Patents for Harrow Eye
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Harrow Eye | NATACYN | natamycin | SUSPENSION;OPHTHALMIC | 050514-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Harrow Eye | TOBRADEX ST | dexamethasone; tobramycin | SUSPENSION/DROPS;OPHTHALMIC | 050818-001 | Feb 13, 2009 | RX | Yes | Yes | 8,450,287 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Harrow Eye | VERKAZIA | cyclosporine | EMULSION;OPHTHALMIC | 214965-001 | Jun 23, 2021 | RX | Yes | Yes | 9,132,071 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Harrow Eye | VEVYE | cyclosporine | SOLUTION;OPHTHALMIC | 217469-001 | May 30, 2023 | RX | Yes | Yes | 11,154,513 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Harrow Eye | ILEVRO | nepafenac | SUSPENSION/DROPS;OPHTHALMIC | 203491-001 | Oct 16, 2012 | RX | Yes | Yes | 9,662,398 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Harrow Eye | VEVYE | cyclosporine | SOLUTION;OPHTHALMIC | 217469-001 | May 30, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Harrow Eye
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Harrow Eye | MOXEZA | moxifloxacin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 022428-001 | Nov 19, 2010 | 6,716,830*PED | ⤷ Try a Trial |
Harrow Eye | VIGAMOX | moxifloxacin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 021598-001 | Apr 15, 2003 | 7,671,070*PED | ⤷ Try a Trial |
Harrow Eye | TOBRASONE | fluorometholone acetate; tobramycin | SUSPENSION/DROPS;OPHTHALMIC | 050628-001 | Jul 21, 1989 | 5,149,693 | ⤷ Try a Trial |
Harrow Eye | NEVANAC | nepafenac | SUSPENSION/DROPS;OPHTHALMIC | 021862-001 | Aug 19, 2005 | 5,475,034 | ⤷ Try a Trial |
Harrow Eye | VIGAMOX | moxifloxacin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 021598-001 | Apr 15, 2003 | 5,849,752*PED | ⤷ Try a Trial |
Harrow Eye | VEXOL | rimexolone | SUSPENSION/DROPS;OPHTHALMIC | 020474-001 | Dec 30, 1994 | 4,686,214 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for HARROW EYE drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Ophthalmic | 0.50% | ➤ Subscribe | 2005-12-22 |
➤ Subscribe | Ophthalmic Solution | 10.5% | ➤ Subscribe | 2012-02-29 |
➤ Subscribe | Ophthalmic Suspension | 0.3% | ➤ Subscribe | 2015-12-21 |
International Patents for Harrow Eye Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Mexico | 2007003045 | ⤷ Try a Trial |
South Korea | 20200106097 | ⤷ Try a Trial |
Spain | 2586381 | ⤷ Try a Trial |
Spain | 2314354 | ⤷ Try a Trial |
European Patent Office | 3722274 | ⤷ Try a Trial |
Portugal | 2262506 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Harrow Eye Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0350733 | 11/2000 | Austria | ⤷ Try a Trial | PRODUCT NAME: MOXIFLOXACIN, DESSEN PHARMAZEUTISCH VERWENDBARE HYDRATE UND SAEUREADDITIONSSALZE, DESSEN ALKALI-ERDALKALI-SILBER- UND GUANIDINIUMSALZE, SOWIE DESSEN C1 - C4 ALKYL- ODER; NAT. REGISTRATION NO/DATE: 1-23494, 1-23495, 1-23496 20000215; FIRST REGISTRATION: DE 45263.00.00 19990621 |
1429780 | 13C0012 | France | ⤷ Try a Trial | PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808 |
1809237 | C01809237/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: CICLOSPORIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66093 08.09.2016 |
1809237 | 300741 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: CICLOSPORINE (EYE DROP EMULSION); REGISTRATION NO/DATE: EU/1/15/990 20150323 |
0663828 | C300085 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103 |
0350733 | 2001C/030 | Belgium | ⤷ Try a Trial | PRODUCT NAME: MOXIFLOXACINE CHLORHYDRATE (CORRESPONDANT A MOXIFLOXACINE); NATL. REGISTRATION NO/DATE: 187 IS 328 F 3 20010507; FIRST REGISTRATION: DE 45263.00.00 19990621 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.